ARA-290 (Cibinetide): EPO's Repair Signal Without the Blood Effects

ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from the helix-B region of erythropoietin. It represents a specific and interesting piece of drug design: separating EPO's tissue-protective activity from its blood-forming activity, which are mediated by different receptors.

This guide situates ARA-290 within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

Erythropoietin's other role

Erythropoietin is known for stimulating red blood cell production through the classical EPO receptor homodimer. Less widely appreciated is that EPO is produced in tissues well beyond the kidney — including brain and peripheral nerve — where making red cells is plainly not the purpose.

In those tissues EPO acts through a different receptor: a heteromeric complex of the EPO receptor with the beta-common receptor, often called the innate repair receptor. Activating this receptor produces anti-inflammatory and tissue-protective effects and supports repair after injury.

This created an obvious therapeutic problem. Giving EPO to exploit tissue protection also raises hematocrit, and elevated red cell mass carries thrombotic and cardiovascular risk — a consequence demonstrated clearly in trials of EPO for other purposes. The desired effect and the dangerous one came together.

How ARA-290 separates the two

The two receptor systems recognize different regions of the EPO molecule. The classical receptor engages one face; the innate repair receptor engages the helix-B domain.

ARA-290 reproduces only that helix-B region as a short 11-amino-acid peptide. The result is a molecule that activates the innate repair receptor without engaging the erythropoietic receptor — tissue protection with no effect on red cell production.

This is a clean illustration of a broader principle in peptide design: a large protein's activities can sometimes be separated by identifying which structural region drives which effect and reproducing only the one wanted. The same logic underlies GHRH(1-29) and Ac-SDKP.

What the clinical work shows

ARA-290 has been studied principally in small fiber neuropathy, a condition affecting the thin nerve fibers carrying pain and temperature sensation, which causes burning pain and autonomic symptoms and has few effective treatments.

Trials have focused on small fiber neuropathy associated with sarcoidosis and on diabetic neuropathy. Reported findings include improvements in patient-reported neuropathic symptom scores and, in some work, changes in corneal nerve fiber measures used as an objective marker of small fiber integrity.

These are relatively small studies in defined populations. The results are encouraging rather than definitive, and ARA-290 has received orphan designation in relevant indications without achieving approval.

The honest position: a well-designed molecule with a coherent mechanism and early clinical signals that have not yet been confirmed in the larger trials required for approval.

Regulatory status

ARA-290 is investigational and not FDA-approved. It is not an established compounding substance, and material sold under this name outside a trial setting is unregulated.

For patients with small fiber neuropathy — who are often genuinely underserved by available options — the appropriate route to this compound is a clinical trial, and the appropriate immediate care is established neuropathic pain management alongside treatment of any underlying cause. Our peptide formulary tracks status across the category.